Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings

Cancer Research

Volumn 73, Issue 12, 2013, Pages 3545-3554

  Ricupito, Alessia ^a,b   Grioni, Matteo ^a   Calcinotto, Arianna ^a,b   Michelini, Rodrigo Hess ^a   Longhi, Renato ^c   Mondino, Anna ^a   Bellone, Matteo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; FEMALE; IMMUNOCOMPETENCE; IN VITRO STUDY; MALE; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTECTION; TUMOR IMMUNITY; WILD TYPE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 84879099045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2449     Document Type: Article

References (50)

1. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 2000;406:793-8.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52. (Pubitemid 28155090)
3. Yang J, Huck SP, McHugh RS, Hermans IF, Ronchese F. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A 2006;103:147-52. (Pubitemid 43076119)
4. Guarda G, Hons M, Soriano SF, Huang AY, Polley R, Martin-Fontecha A, et al. L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 2007;8:743-52. (Pubitemid 46965350)
5. Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, et al. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 2006;55:254-67. (Pubitemid 41682574)
6. Nolz JC, Harty JT. Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv Exp Med Biol 2011;780:69-83.
7. Bellone M. Apoptosis, cross-presentation, and the fate of the antigen specific immune response. Apoptosis 2000;5:307-14.
8. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 2010;33:451-63.
9. Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011;29:8501-5.
10. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008;8:74-80.
11. Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, et al. Relevance of the tumor antigen in validation of three vaccination strategies for melanoma. J Immunol 2000;165:2561-656.
12. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001;11:245-60.
13. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classi fication. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305. (Pubitemid 38339483)
14. Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005;35:66-75.
15. Degl'Innocenti E, Grioni M, Capuano G, Jachetti E, Freschi M, Bertilaccio MTS, et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+ CD25+ regulatory T cells. Cancer Res 2008;68:292-300.
16. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 1985;162:1745-59. (Pubitemid 16149673)
17. Tanaka Y, Tevethia SS. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. J Immunol 1988;140:4348-54.
18. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161-214. (Pubitemid 20126875)
19. Camporeale A, Boni A, Iezzi G, Degl'Innocenti E, Grioni M, Mondino A, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003;63:3688-94. (Pubitemid 36793053)
20. Millrain M, Chandler P, Dazzi F, Scott D, Simpson E, Dyson PJ. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J Immunol 2001;167:3756-64. (Pubitemid 32910821)
21. Hess Michelini R, Freschi M, Manzo T, Jachetti E, Degl'Innocenti E, Grioni M, et al. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors. Cancer Res 2010;70:3505-14.
22. Bertilaccio MT, Grioni M, Sutherland BW, Degl'Innocenti E, Freschi M, Jachetti E, et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 2008;68:1105-15. (Pubitemid 351875182)
23. Mylin LM, Deckhut AM, Bonneau RH, Kierstead TD, Tevethia MJ, Simmons DT, et al. Cytotoxic T lymphocyte escape variants, induced mutations, and synthetic peptides define a dominant H-2Kb-restricted determinant in simian virus 40 tumor antigen. Virology 1995;208:159-72.
24. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000;105:R9-R14. (Pubitemid 30164122)
25. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007;25:171-92. (Pubitemid 46697906)
26. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001;19:2666-72. (Pubitemid 32234287)
27. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, et al. Identi fication of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;185:453-9. (Pubitemid 27078363)
28. Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, et al. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J Immunol 1997;158:783-9. (Pubitemid 127492655)
29. Cui W, Kaech SM. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev 2010;236:151-66.
30. Butler NS, Nolz JC, Harty JT. Immunologic considerations for generating memory CD8 T cells through vaccination. Cell Microbiol 2011;13:925-33.
31. Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, et al. In vivo administration of arti ficial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res 2009;69:9376-84.
32. Badovinac VP, Messingham KAN, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 2005;11:748-56. (Pubitemid 41021207)
33. LaCelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 2009;15:6881-90.
34. Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, et al. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol 2007;179:5024-32.
35. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cellmemory. Nat Rev Immunol 2008;8:107-19.
36. Wirth TC, Xue H-H, Rai D, Sabel JT, Bair T, Harty JT, et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8+ T cell differentiation. Immunity 2010;33:128-40.
37. Fernando GJ, Khammanivong V, Leggatt GR, Liu WJ, Frazer IH. The number of long-lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation. Eur J Immunol 2002;32:1541-9. (Pubitemid 34679142)
38. Zinkernagel RM. On differences between immunity and immunological memory. Curr Opin Immunol 2002;14:523-36. (Pubitemid 34671257)
39. Wherry EJ. T cell exhaustion. Nat Immunol 2011;131:492-9.
40. Pearce EL, Shen H. Generation of CD8T cell memory is regulated by IL-12. J Immunol 2007;179:2074 -81.
41. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/ macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009;15:7029-35.
42. Morton DL, Mozzillo N,Thompson JF, Kelley MC, Faries MB, Wagner J, et al. An international, randomized, phase III trial of bacillus Calmette- Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25:8508.
43. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010;10:787-96.
44. Dranoff G. Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 2012;12:61-6.
45. Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, et al. Prolonged survival after complete resection of disseminated melanomaand active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002;20:4549-54. (Pubitemid 35402957)
46. Eggermont AM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7.
47. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15. (Pubitemid 39273730)
48. Thompson IM. Chemoprevention of prostate cancer: agents and study designs. J Urol 2007;178:S9-S13. (Pubitemid 47211163)
49. Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 2012;61:453-68.
50. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8 +memory T cells. J Exp Med 1997;186:859-65. (Pubitemid 27407347)